2021 IBCN Update Series

IBCN Update on ctDNA Sept 25, 2021

IBCN Update on Bladder Preservation after Neoadjuvant Therapy Oct 30, 2021

IBCN Update on Biology of BCG Response Dec 4, 2021

2020 Annual Meeting Video Library

Annual Meeting Video

Inaugural Virtual Visiting Clawater Professor

Ashish Kamat, MD, MBBS

Poster Sessions – Translational

Mutational signature modelling in vitro recapitulates bladder cancer initiation

Investigating sexual dimorphism in the tumour immune microenvironment of non-muscle invasive bladder cancer

Proteins Involved in Mitochondrial Biogenesis, Dynamics and Respiratory Complex I Activity are Increased in Bladder Cancer and are Inversely Associated with Tumor Aggressiveness

Organotypic model and in vitro modeling or urothelial carcinoma give different cellular responses to proteinase activated receptor (PAR) agonism and antagonism

An evaluation of single-sample tumor subtype classification methods

Cytotoxic and genotoxic effects of epigenetic inhibitors on bladder cancer cells

Tumor Immune Microenvironment in Responde to Radiotherapy vs BCG in a Murine Model of Bladder Cancer

An exploratory proteomic study delineating the local and systemic immune-oncologic profile of urinary bladder cancer patients

RBM10: The role of splicing factor in urothelial homeostatis and tumorigenesis

FBXW7 loss of function contributes to worse overall survival and associates with MYC accumulation in muscle invasive bladder cancer

The potential for designing urothelial carcinomas using pluripotent stem cell-based systems

Genomic and transcriptomic characterization of metastatic urothelial carcinoma

Improving oncolytic virotherapy efficacy using target therapies against molecules of cell cycle control

Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer

Radiosensitization of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota

Regulation of PPARg expression in luminal muscle invasive bladder cancer

Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

Poster Sessions – Clinical

Role of blue light cystoscopy in detecting invasive bladder tumor: Data from multi-institutional registry

Role of CA125 CA19-9 & CEA in predicting outcome following neoadjuvant chemotherapy (NAChT) in muscle invasive bladder cancer (MIBC)

Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma

Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer

Divergent immunol correlates of PD-L1 scoring algorithms in muscle-invasive urothelial bladder cancer correlate with different patient outcomes

Predictive and prognostic performance of IHC3-Uro immunohistochemistry-based molecular subtyping in muscle-invasive bladder cancer

Transition of ANXA10 expression is a useful dianostic and prognostic marker in upper tract urothelial carcinoma

Restaging Transurethral Resection of HG Ta Urothelial Carcinoma: A Risk-Adapted Approach

Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial

Measureable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease in Patients with High-Grade Non-Muscle Invasive Bladder Cancer

CtDNA as a Predictor of Outcome

CBI after Turbt for Prevention of NMBIC Recurrence: A Systematic Review

Lytic Effects of Water on Bladder Cancer Cell Lines: Implications for CBI for Reduction of Recurrence

Protective effect of BCG bladder instillations on pneumonia?

Comparing Cost of Radical vs Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care

Geographic Distribution of Racial Differences in Bladder Cancer Mortality in the United States: A Nationwide Population-Based Study

Long-Term Outcomes and Cost Among BCG-treated High Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting

Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States

Abstract Sessions – Translational Track

Molecular Profiling of Post-Pembrolizumab Muscle Invasive Bladder Cancer (MIBC) Reveals Unique Features that may Inspire NEw Sequential Therapies in Pathological Non-Responders

Recombinant BCG Overexpressing STING Agonist Elicits Trained Immunity and Improved Antitumor Efficacy in Non-Muscle Invasive Bladder Cancer

Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis

NER Pathway Deficiency in Bladder Cancer

Recurring Urothelial Carcinomas are Clonal but Incompatible with a Direct Relationship

Abstract Sessions – Basic Research Track

Development and Characterization of a Novel Autochthonous Semi-spontaneous Bladder Cancer Model by Pathological Examination, Single Cell RNA Sequencing and Proteomic Profiling

Cisplatin-Based NAC

Identification of New Driver and Passenger Mutations within APOBEC-Induced Hotspot Mutations in Bladder Cancer

STAG2 and PPARg as Drivers of Luminal-Type Bladder Cancer

Extraction-Free Comprehensive Transcriptome Squencing of Carcinoma In-SITU is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer

Abstract Sessions – Clinical Track

Germline-somatic Interactions in the Bladder Cancer Genome

Specific Genetic Susceptibility Patterns of the Urothelial Bladder Cancer Taxonomic Subtypes

Drug Repurposing for Bladder Cancer Driven by Patients’ Proteomic Signatures

Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guerin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14

Impact of Upper Tract Urothelial Carcinoma on Outcomes of Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin

State of the Art Talks

Keynote: Improving Immune Checkpoint Inhibitor Therapy in Cancer

The Ariadne’s Thread of FGFR3